S&P 500   4,583.34 (+1.12%)
DOW   35,386.80 (+1.02%)
QQQ   371.54 (+1.38%)
AAPL   168.36 (+1.28%)
MSFT   310.17 (+2.25%)
FB   326.16 (+2.06%)
GOOGL   2,736.46 (+1.26%)
AMZN   3,154.74 (+0.92%)
TSLA   1,024.59 (+2.91%)
NVDA   253.21 (+1.01%)
BABA   133.29 (+4.34%)
NIO   29.87 (+4.33%)
AMD   125.78 (-1.94%)
CGC   7.91 (+3.53%)
MU   87.52 (-2.76%)
GE   100.39 (-0.23%)
T   27.03 (-0.92%)
F   22.29 (-0.71%)
DIS   151.55 (+0.96%)
AMC   18.64 (+1.75%)
PFE   53.44 (-0.19%)
ACB   4.93 (+1.44%)
BA   217.31 (+0.11%)
S&P 500   4,583.34 (+1.12%)
DOW   35,386.80 (+1.02%)
QQQ   371.54 (+1.38%)
AAPL   168.36 (+1.28%)
MSFT   310.17 (+2.25%)
FB   326.16 (+2.06%)
GOOGL   2,736.46 (+1.26%)
AMZN   3,154.74 (+0.92%)
TSLA   1,024.59 (+2.91%)
NVDA   253.21 (+1.01%)
BABA   133.29 (+4.34%)
NIO   29.87 (+4.33%)
AMD   125.78 (-1.94%)
CGC   7.91 (+3.53%)
MU   87.52 (-2.76%)
GE   100.39 (-0.23%)
T   27.03 (-0.92%)
F   22.29 (-0.71%)
DIS   151.55 (+0.96%)
AMC   18.64 (+1.75%)
PFE   53.44 (-0.19%)
ACB   4.93 (+1.44%)
BA   217.31 (+0.11%)
S&P 500   4,583.34 (+1.12%)
DOW   35,386.80 (+1.02%)
QQQ   371.54 (+1.38%)
AAPL   168.36 (+1.28%)
MSFT   310.17 (+2.25%)
FB   326.16 (+2.06%)
GOOGL   2,736.46 (+1.26%)
AMZN   3,154.74 (+0.92%)
TSLA   1,024.59 (+2.91%)
NVDA   253.21 (+1.01%)
BABA   133.29 (+4.34%)
NIO   29.87 (+4.33%)
AMD   125.78 (-1.94%)
CGC   7.91 (+3.53%)
MU   87.52 (-2.76%)
GE   100.39 (-0.23%)
T   27.03 (-0.92%)
F   22.29 (-0.71%)
DIS   151.55 (+0.96%)
AMC   18.64 (+1.75%)
PFE   53.44 (-0.19%)
ACB   4.93 (+1.44%)
BA   217.31 (+0.11%)
S&P 500   4,583.34 (+1.12%)
DOW   35,386.80 (+1.02%)
QQQ   371.54 (+1.38%)
AAPL   168.36 (+1.28%)
MSFT   310.17 (+2.25%)
FB   326.16 (+2.06%)
GOOGL   2,736.46 (+1.26%)
AMZN   3,154.74 (+0.92%)
TSLA   1,024.59 (+2.91%)
NVDA   253.21 (+1.01%)
BABA   133.29 (+4.34%)
NIO   29.87 (+4.33%)
AMD   125.78 (-1.94%)
CGC   7.91 (+3.53%)
MU   87.52 (-2.76%)
GE   100.39 (-0.23%)
T   27.03 (-0.92%)
F   22.29 (-0.71%)
DIS   151.55 (+0.96%)
AMC   18.64 (+1.75%)
PFE   53.44 (-0.19%)
ACB   4.93 (+1.44%)
BA   217.31 (+0.11%)
NASDAQ:AMED

Amedisys Stock Forecast, Price & News

$136.79
+3.77 (+2.83%)
(As of 01/20/2022 09:45 AM ET)
Add
Compare
Today's Range
$134.72
$136.79
50-Day Range
$133.02
$182.79
52-Week Range
$132.79
$325.12
Volume
54 shs
Average Volume
274,734 shs
Market Capitalization
$4.46 billion
P/E Ratio
20.54
Dividend Yield
N/A
Beta
0.7
30 days | 90 days | 365 days | Advanced Chart
Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.


Amedisys logo

About Amedisys

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Headlines

Amedisys (NASDAQ:AMED) Hits New 52-Week Low at $133.11
January 19, 2022 |  americanbankingnews.com
Amedisys (NASDAQ:AMED) Trading Down 7.7%
January 10, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
21,000
Year Founded
1982

Sales & Book Value

Annual Sales
$2.07 billion
Cash Flow
$8.35 per share
Book Value
$24.71 per share

Profitability

Net Income
$183.61 million
Pretax Margin
13.39%

Debt

Price-To-Earnings

Miscellaneous

Free Float
32,015,000
Market Cap
$4.46 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
1/20/2022
Next Earnings (Estimated)
2/23/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.32 out of 5 stars

Medical Sector

260th out of 1,415 stocks

Home Health Care Services Industry

7th out of 9 stocks

Analyst Opinion: 4.3Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Amedisys (NASDAQ:AMED) Frequently Asked Questions

Is Amedisys a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 1 sell rating, 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys
or view top-rated stocks.

How has Amedisys' stock been impacted by Coronavirus?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMED shares have decreased by 19.8% and is now trading at $136.79.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 1,030,000 shares, an increase of 30.4% from the December 15th total of 789,800 shares. Based on an average daily volume of 414,900 shares, the short-interest ratio is presently 2.5 days. Approximately 3.2% of the shares of the company are sold short.
View Amedisys' Short Interest
.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Amedisys
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) posted its quarterly earnings results on Tuesday, November, 2nd. The health services provider reported $1.53 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.16. The health services provider earned $553.49 million during the quarter, compared to analyst estimates of $568.55 million. Amedisys had a trailing twelve-month return on equity of 24.15% and a net margin of 9.98%. During the same period in the prior year, the business earned $2.24 EPS.
View Amedisys' earnings history
.

How will Amedisys' stock buyback program work?

Amedisys announced that its board has authorized a share repurchase program on Wednesday, August 4th 2021, which permits the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of $5.880-$5.930 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.080. The company issued revenue guidance of $2.20 billion-$2.21 billion, compared to the consensus revenue estimate of $2.25 billion.

What price target have analysts set for AMED?

14 equities research analysts have issued 1-year price objectives for Amedisys' stock. Their forecasts range from $150.00 to $235.00. On average, they anticipate Amedisys' share price to reach $205.36 in the next twelve months. This suggests a possible upside of 50.1% from the stock's current price.
View analysts' price targets for Amedisys
or view top-rated stocks among Wall Street analysts.

Who are Amedisys' key executives?

Amedisys' management team includes the following people:

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (4.87%), Frontier Capital Management Co. LLC (0.53%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.01%), Icon Wealth Partners LLC (0.01%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Amedisys stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys
.

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Icon Wealth Partners LLC, Crossmark Global Holdings Inc., State of Alaska Department of Revenue, and Parallel Advisors LLC. Company insiders that have sold Amedisys company stock in the last year include Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, and Scott G Ginn.
View insider buying and selling activity for Amedisys
or view top insider-selling stocks.

Which major investors are buying Amedisys stock?

AMED stock was acquired by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Integrated Investment Consultants LLC, Exchange Traded Concepts LLC, and Louisiana State Employees Retirement System. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Richard A Lechleiter, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys
or or view top insider-buying stocks.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $136.79.

How much money does Amedisys make?

Amedisys has a market capitalization of $4.46 billion and generates $2.07 billion in revenue each year. The health services provider earns $183.61 million in net income (profit) each year or $6.66 on an earnings per share basis.

How many employees does Amedisys have?

Amedisys employs 21,000 workers across the globe.

When was Amedisys founded?

Amedisys was founded in 1982.

What is Amedisys' official website?

The official website for Amedisys is www.amedisys.com.

Where are Amedisys' headquarters?

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at (225) 292-2031, via email at [email protected], or via fax at 225-292-8163.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.